⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for egfr l858r

Every month we try and update this database with for egfr l858r cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970
Nonsquamous Non...
EGFR L858R
EGFR Exon 19 De...
Patritumab Deru...
Platinum-based ...
18 Years - Daiichi Sankyo
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI TherapyNCT05338970
Nonsquamous Non...
EGFR L858R
EGFR Exon 19 De...
Patritumab Deru...
Platinum-based ...
18 Years - Daiichi Sankyo
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Nerv...
EGFR T790M
EGFR C797S
EGFR L858R
EGFR Gene Mutat...
EGF-R Positive ...
EGFR Exon 19 De...
EGFR Mutation R...
EGFR Activating...
Protein Kinase ...
Antineoplastic ...
Thoracic Neopla...
BLU-945
osimertinib
18 Years - Blueprint Medicines Corporation
A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)NCT06053099
Non Small Cell ...
EGFR Activating...
EGFR DEL19
EGFR L858R
Plasma ctDNA
FFPE blocks
18 Years - Intergroupe Francophone de Cancerologie Thoracique
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCNCT05153408
Lung Neoplasm
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Nerv...
EGFR C797S
EGFR C797A
EGFR L858R
EGFR Exon 19 De...
EGFR Gene Mutat...
EGF-R Positive ...
EGFR Mutation R...
EGFR Activating...
Thoracic Neopla...
Antineoplastic ...
Protein Kinase ...
EGFR C797G
EGFR C797X
Non Small Cell ...
BLU-701
osimertinib
carboplatin
pemetrexed
18 Years - Blueprint Medicines Corporation
(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCNCT04862780
Lung Neoplasms
Carcinoma, Non-...
Respiratory Tra...
Neoplasms
Neoplasms by Si...
Lung Diseases
Respiratory Tra...
Carcinoma, Bron...
Bronchial Neopl...
Adenocarcinoma
Carcinoma
Neoplasms by Hi...
Neoplasms, Nerv...
EGFR T790M
EGFR C797S
EGFR L858R
EGFR Gene Mutat...
EGF-R Positive ...
EGFR Exon 19 De...
EGFR Mutation R...
EGFR Activating...
Protein Kinase ...
Antineoplastic ...
Thoracic Neopla...
BLU-945
osimertinib
18 Years - Blueprint Medicines Corporation
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: